AN2 Therapeutics, Inc.ANTXNASDAQ

Revenue (LTM)

Net Income (LTM)

$-35M

+31.5% YoY

Free Cash Flow

$-30M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.0B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	0	0
Gross Profit	0	-0	0	0	0
Operating Income	-22	-42↓95.9%	-70↓64.8%	-55↑21.7%	-38↑30.1%
Net Income	-22	-41↓90.1%	-65↓58.1%	-51↑20.7%	-35↑31.5%
EBITDA	-22	-41↓89.5%	5↑112.0%	3↓34.1%	-38↓1278.8%
EPS Diluted	-1.50	-2.79↓86.0%	-2.74↑1.8%	-1.72↑37.2%	-1.16↑32.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	12	27↑125.0%	16↓42.5%	21↑36.5%	20↓6.6%
Total Current Assets	60	99↑64.1%	111↑12.1%	86↓21.9%	60↓30.5%
Total Assets	65	103↑57.0%	139↑35.3%	92↓33.6%	62↓32.7%
Total Current Liabilities	3	7↑111.7%	14↑95.4%	10↓27.1%	9↓14.8%
Total Liabilities	3	7↑110.9%	14↑95.4%	10↓27.1%	9↓13.2%
Total Equity	62	95↑54.1%	125↑30.8%	82↓34.4%	53↓35.2%
Total Debt	0	0	0	0	0
Net Debt	-12	-27↓124.6%	-16↑42.4%	-21↓36.5%	-20↑6.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-20	-33↓63.4%	-53↓59.2%	-49↑7.6%	-30↑39.4%
Capital Expenditure	0	0	0	0	0
Free Cash Flow	-20	-33↓63.4%	-53↓59.2%	-49↑7.6%	-30↑39.4%
Stock-Based Comp	1	4↑350.8%	8↑91.6%	8↓0.9%	6↓25.1%
Net Change in Cash	8	15↑88.4%	-12↓176.5%	6↑149.3%	-1↓124.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance